Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers

Calithera Bio­sciences will be go­ing in­to the new year with on­ly two-thirds of its staff.

The South San Fran­cis­co-based biotech is lay­ing off “around 30 em­ploy­ees,” it told End­points News — or 35% of its to­tal work­force — in the wake of a Phase II flop. Adding Calithera’s tela­gle­na­s­tat to Ex­elix­is’ Cabome­tyx, the in­ves­ti­ga­tors con­clud­ed, failed to im­prove pro­gres­sion-free sur­vival for pa­tients with re­nal cell car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER